Andexxa Vs 4F-PCC in ICH: An Ongoing Debate
November 28, 2022
BACKGROUND: Direct oral anticoagulants (DOACs) such as rivaroxaban [Xarelto] and apixaban [Eliquis] have become more prevalent in the aging population and are associated with intracranial...
Marco Torres
Andexanet Alfa Vs. Four-Factor PCC: Is Andexanet Alfa Worth The Hype?
February 28, 2022
Background: Oral factor Xa inhibitors (FXi) have been associated with major and fatal bleeding events, including intracranial hemorrhage (ICH). In randomized controlled trials, both rivaroxaban...
ANNEXA-4: Andexanet Alfa and Factor Xa Inhibitors
March 4, 2019
Background: Over the past few years we have seen a surge in the use of oral Factor Xa inhibitors (apixaban, rivaroxaban etc) for anticoagulation. The reason...
Episode 89 – DOACs Part 2: Bleeding and Reversal Agents
December 6, 2016
In this Part 2, DOACs Bleeding and Reversal we discuss the management of bleeding in patients taking DOACs with minor risk bleeds, like epistaxis where...
Anton Helman